Insights On CONTRACT PHARMA MANUFACTURING

  1. Partnering For Success: Microbiological Testing In Contract Laboratories 8/12/2026

    Outsourcing microbiological testing goes beyond method selection. Learn how early lab engagement, redundancy planning, and regulatory alignment protect your release timelines and compliance.

  2. In Silico Immunogenicity Assessment For Peptides 8/11/2026

    Predict immunogenic risks in peptides with unnatural amino acids using in silico workflows. High-accuracy simulations predict HLA binding to accelerate safety assessments and regulatory approvals.

  3. Packaging And Labeling Support For A Global Cell Therapy Program 8/10/2026

    Master complex cell therapy logistics with coordinated depots, purpose-built labeling, and temperature-controlled solutions that protect product integrity.

  4. Improving Clinical Trial Label Translation Through Centralized Reuse And Control 8/10/2026

    Eliminate workflow inefficiencies and regulatory risk in global trials with a centralized translation framework and validated phrase library for consistent, cost-effective execution.

  5. When Every Hour Counts: Emergency Transfer Protects Critical Biomedical Materials 8/10/2026

    Rapid deployment of specialized cold chain logistics and cryogenic assets ensures strict temperature compliance, protecting critical research continuity and preventing catastrophic material loss.

  6. From DNA To IND In 6 Months: Accelerated Development Backed By Experience 8/10/2026

    A rapid, integrated biologics development strategy can achieve IND readiness in as little as six months by combining parallel workflows, early risk mitigation, advanced technologies, robust analytics, and regulatory planning.

  7. Why A Strong CMC Roadmap Is Essential For Cell Therapy Program Success 8/8/2026

    A structured regulatory roadmap and early management of manufacturing, materials, and assay testing help reduce risk and prevent costly delays in cell therapy development.

  8. Late-Phase Process Development Capabilities Are Stronger Than Ever 8/8/2026

    Late-phase cell therapy programs require process control, automation, and characterization to improve consistency, reduce regulatory risk, and enable commercial-scale manufacturing.

  9. How To Build A Cell Therapy CMC Roadmap 8/8/2026

    A structured, phase-appropriate regulatory roadmap helps cell therapy developers reduce risk, streamline manufacturing and testing, and avoid costly clinical delays.

  10. Reducing The Time And Cost Of Robust Analytical Method Development 8/8/2026

    Design-of-experiment methodology accelerates cell therapy assay development, reducing costs and timelines while improving assay robustness, regulatory readiness, and data-driven decision-making.